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Ion channelThe M2 protein of inﬂuenza A virus performs the crucial function of transporting protons to the interior of
virions enclosed in the endosome. Adamantane drugs, amantadine (AMN) and rimantidine (RMN), block the
proton conduction in some strains, and have been used for the treatment and prophylaxis of inﬂuenza A
infections. The structures of the transmembrane (TM) region of M2 that have been solved in micelles using
NMR (residues 23-60) (Schnell and Chou, 2008) and by X-ray crystallography (residues 22-46) (Stouffer et
al., 2008) suggest different drug binding sites: external and internal for RMN and AMN, respectively. We
have used molecular dynamics (MD) simulations to investigate the nature of the binding site and binding
mode of adamantane drugs on the membrane-bound tetrameric M2-TM peptide bundles using as initial
conformations the low-pH AMN-bound crystal structure, a high-pH model derived from the drug-free crystal
structure, and the high-pH NMR structure. The MD simulations indicate that under both low- and high-pH
conditions, AMN is stable inside the tetrameric bundle, spanning the region between residues Val27 to
Gly34. At low pH the polar group of AMN is oriented toward the His37 gate, while under high-pH conditions
its orientation exhibits large ﬂuctuations. The present MD simulations also suggest that AMN and RMN
molecules do not show strong afﬁnity to the external binding sites.a), mlklein@temple.edu
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
The M2 protein located in the lipid envelope of inﬂuenza A virus is
activated by the low pH in the endosome, which encloses viral
particles following endocytosis [1]. M2 transports protons to the
interior of the virion, which then permits uncoating of the viral RNA
and allows fusion of the viral envelope with the endosomal bilayer: a
process essential for the viral RNA release and continuation of the
infectious life cycle. The M2 protein is a homo-tetramer with each
monomer consisting of three regions: a 24-residue N-terminal
domain, a transmembrane (TM) domain of 19 residues, and a 54-
residue cytoplasmic domain. Adamantane derivatives, amantadine
(AMN) and rimantadine (RMN), block the M2 channel activity, and
hence can be used for prophylaxis and treatment of inﬂuenza A
infections [2]. However, the resistance to adamantane drugs has
signiﬁcantly increased in the last decade [3], leading to the urgent
need for developing new and effective drugs targetingM2. Besides the
M2 protein, the neuraminidase protein of the virus is the other major
target protein of the currently available anti-ﬂu drugs, oseltamivir
(Tamiﬂu) and zanamivir (Relenza). However, the resistance tooseltamivir has also greatly increased in the last two years, while
the use of zanamivir suffers from the problem of poor bioavailability
of the drug [4,5]. Thus, the increasing resistance to the currently
available drugs calls for the urgent development of new and more
potent drugs targeting seasonal and pandemic strains of inﬂuenza A
virus.
There is a signiﬁcant body of research that has focused on residues
22-46 of the M2 protein (hereafter referred to as M2-TM), which
includes the TM domain with a few hydrophilic residues on either
end. M2-TM forms conductive tetrameric bundles, which are able to
bind AMN [6–10]. Although model structures of M2-TM were
available for some time [9,11–15], high resolution structures have
now been solved using NMR [16] and X-ray crystallography [17].
Speciﬁcally, Schnell and Chou reported a RMN-bound ensemble of 15
structures for a four-helix bundle of M2 residues 23-60 using NMR on
micelles samples, under conditions which likely correspond to high
pH [16]. The crystal structure of M2-TMwith bound AMN, reported by
Stouffer et al., represents instead a low-pH conformation of M2-TM
[17]. The two structural studies, while capturing conformations of the
channel at different pH conditions, propose very different mechan-
isms of channel inhibition by adamantane drugs. In the crystal
structure, AMN is bound in the central cavity of M2-TM, spanning the
region containing residues Val27-Gly34 [17]. This binding mode is
consistent with a pore-blockingmechanism of proton conduction, and
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mutations found in resistant ﬂu strains, including swine H1N1 and
avian H5N1 viruses [18,19]. On the other hand, the NMR structure
contains four RMN molecules bound to the outer surface of the M2
(residues 23-60) tetramer, close to Asp44. In the NMR structure the
binding site is located far from principal resistant sites, and an
allosteric mechanism has been proposed to rationalize the blocking of
proton conduction [16]. Questions about the drug binding site of the
M2 protein bundle raised by the two structures were discussed by
Miller [20].
Although the low resolution (3.5 Å) of the AMN-bound crystal
structure permits the identiﬁcation of the binding site of AMN in the
channel cavity, it does not deﬁnitively allow determination of the
orientation of the drug polar head group. Stouffer et al. proposed that
the most plausible orientation of the AMN amide group is toward the
C-terminal end of the bundle, enabling the bulky hydrophobic part of
AMN to interact with the hydrophobic internal residues around Val27,
while the charged head group can be accommodated in the solvated
internal cavity. The location and orientation of AMN in the bundle
cavity found by the molecular dynamics (MD) study of Yi et al. [21]
agree with the suggestion of Stouffer et al. Chen et al. have also shown
usingMD simulations that AMN binds to the Ala29 region and reduces
the proton conductance of M2 by 99.8% [22]. They noted that the
primary proton permeation free energy barrier is relocated from
His37 to Ala29 region as a result of AMN binding. Moreover, Jing et al.
have reported that M2 from inﬂuenza A with the mutation Asp44Ala
is sensitive to AMN as measured by electrophysiological recordings in
Xenopus laevis oocytes and in mammalian cells [23]. Recently,
Balannik et al. have also reported that mutations of residues that
are N-terminal to His37 [Val27, Ala30, Ser31 and Gly34] exhibit
signiﬁcantly lower inhibition by AMN while most mutations of
residues which are C-terminal to His37 and far from the internal
binding site [Trp41 and Asp44] have little or no effect on AMN
inhibition [24]. Thus, these data suggest that Asp44 is not required for
AMN sensitivity and the inhibitory binding site is not located outside
the cavity as proposed by the NMR structure. However, the functional
and structural experiments by Pielak et al. support the external lipid-
facing pockets as the primary binding sites [25]. A very recent solid-
state NMR study under high-pH conditions (pH 7.5) shows that
indeed two binding sites (internal and external) do exist in M2 in
phospholipid bilayers, though the external binding site is of much
lower afﬁnity than the internal site and is bound only when the drug
reaches very high concentration [26]. In this paper, we investigate
both the binding sites using MD simulations, which provide us
molecular level insight into the drug binding in a native-like lipid
environment and enable us to build a comprehensive scheme of drug
binding under different pH conditions.
We proposed that M2-TM acts like a ‘proton transporter’ rather
than a classic ‘proton channel’ based on MD simulations of M2-TM in
DMPC bilayers using the drug-free crystal structure and a high-pH
model derived from the crystal structure as initial conformations [27].
This view reconciles the known electrophysiological properties of M2,
such as the low proton conduction rate, the conductance saturation at
low pH, and the strong rectifying behavior [28,29]. The His37 gate of
M2 is involved in the proton selectivity [30,31], and is closed under
external high-pH conditions; while the hydrophobic Val27 gate is
open (Openout-Closedin state). Under conditions of external low pH
that exist inside the endosome, protons reach the central cavity
through the open Val27 gate and the His37 residues get protonated.
This leads to the opening of the His37 gate and the closing of the Val27
gate (Closedout-Openin state). Protons can diffuse from His37 to the
interior of the virus and the protein goes back to the Openout-Closedin
state. Hence, protons are transported to the interior of the virus and
the cycle continues until equilibrium is reached [Fig. 5 of [27]]. It is
interesting to consider the impact of adamantane drugs on the
proposed model for proton conduction by M2.AMN is known to inhibit M2 at both low and high pH [6,32,33], and
Cross and co-workers showed that AMN binds to M2-TM in
spectroscopically distinct manners at low versus high pH [6]. AMN
and RMN are very similar structurally, sharing the adamantane group
and the polar amine group. They affect proton translocation in similar
ways, and bind to M2 with a stoichiometry of one drug per tetramer
[2,10]. Although AMN binds to M2 with slightly lower afﬁnity, their
mechanism of inhibition is thought to be primarily the same [2,10,33].
Herein, we report the results of MD simulations performed to shed
light on the nature of the drug-bindingmode to the tetramericM2-TM
bundle. For membrane-bound M2-TM peptide bundles we ﬁnd that
for all protonation states of His37 examined (i.e., mimicking both
high- and low-pH conditions), AMN binds in the central pore of the
bundle, although the preferred orientation of the amine group within
the pore changes as local pH conditions change. Moreover, in the
membrane environment, adamantane drugs do not show signiﬁcant
afﬁnity for external binding sites located close to Asp44 as proposed
by the NMR studies on micelle-bound M2-TM peptide bundles.
2. Methods
A summary of all the MD simulations including the length of the
peptide used, simulation time and backbone rmsd is provided in
Table 1. The AMN-bound crystal structure obtained by Stouffer et al.
(PDB code: 3C9J; residues 22-46) was used as the initial structure in
the +3 (three His37 protonated) [MD1] and +4 (all His37
protonated) [MD2] protonation states to investigate the drug binding
mechanism under low-pH conditions [17]. As seen from the rmsd
values in Table 1 the structure employed is stable for the ∼20 ns
timescale in both MD simulations. The NMR structures reported by
Schnell and Chou were used to investigate drug binding under high-
pH conditions [16]. MD simulations of the NMR structure (PDB code:
2RLF; residues 23-60) with four AMN molecules bound externally
[MD3], four RMN molecules bound externally [MD4] and one AMN
bound internally [MD5] were also stable on the multi-ns timescale
with low rmsd values (Table 1). Finally, the AMN-bound model
derived from the replication of chain D of the drug-free crystal
structure (D4 model obtained from PDB code: 3BKD; residues 22-46)
[MD6] [27,17] was also used to study drug binding at high-pH
conditions. The MD3, MD4, MD5 and MD6 simulations provide clues
about drug binding under high-pH conditions.
In all of the MD simulations, protein structures were inserted in
the transmembrane orientation into an equilibrated and hydrated 1,2-
dimyristoyl-sn-glycero-3-phosphocholine (DMPC) bilayer patch con-
taining 64 lipids in each leaﬂet to reproduce an in vivo-like
environment, which neither the X-ray crystallography nor the NMR
micelle sample is able to reproduce. The lipid and water molecules
overlapping with the protein were removed. Sodium and chloride
ions were added to the MD system at 150 mM concentration to
maintain overall charge neutrality using the ‘Autoionize’ plugin of
VMD [34]. The system sizes ranged from ∼24,000 to ∼50,000 atoms.
All MD simulations were performed using the code NAMD [35] with
the CHARMM22 protein force ﬁeld [36], CHARMM27 lipid force ﬁeld
[37] and TIP3P water model [38]. The amantadine (C10H18N+)
molecule was constructed and a gas phase optimization was
performed at the B3LYP level with a 6-31G* basis set using the
GAUSSIAN package [39]. Partial atomic charges were assigned via the
RESP scheme [40] in which they are optimized to best reproduce the
quantum electrostatic potential calculated on a set of grid points
around the molecule with an additional penalty function. The
intermolecular potential parameters were taken directly from the
CHARMM force ﬁeld and the equilibrium bond and angle values were
taken from the optimized ab initio structure, which is rigid with
respect to torsions. The charges and parameters for rimantadine
(C12H22N+)were derived in a similar fashion. The protonation state of
the His37 tetrad is zero in all the MD simulations using the NMR
Fig. 1. Internal binding at low pH. Snapshot taken from the MD2 simulation of the
crystal structure with AMN bound in the channel cavity. Val 27 (ice blue), Ser 31
(yellow) and His 37 (orange) are indicated. (A) Front view, (B) N-term view, and (C) C-
term view.
Table 1
Summary of all the MD simulations reported in this work.
MD label PDB code Length of peptide His37 protonation Unconstrained MD time (ns) Backbone rmsd (Å) Drug site
MD1 3C9J 22-46 +3 21.4 2.47±0.67 AMN; internal
MD2 3C9J 22-46 +4 24.7 1.79±0.51 AMN; internal
MD3 2RLF 23-60 0 17.0 1.53±0.18a AMN; external
MD4 2RLF 23-60 0 24.8 2.09±0.26a RMN; external
MD5 2RLF 23-60 0 17.9 2.17±0.23a AMN; internal
MD6 3BKD (D4) 22-46 0 29.7 2.53±0.65 AMN; internal
a Backbone rmsd for only the transmembrane part is reported (residues 23–46 of the NMR structure).
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molecules were inserted randomly in the initial structure in the
channel cavity close to His37 in MD3 andMD5 respectively. AMNwas
docked in the cavity of the NMR structure using VMD with its polar
group pointing toward the His37 in the initial structure.
The temperature was maintained in all the simulations at 310 K by
coupling to a heat bath using the ‘temperature coupling’ method of
NAMD. The energy minimizations of all the systems were followed by
equilibration runs. During the equilibration runs for the systems in
which AMN was bound internally (MD1, MD2, MD5 and MD6) ﬁrst
the heavy atoms of the protein were constrained for 1 ns; followed by
1 ns of harmonic constraints on the Cα atoms. A force constant of
10 kcal/mol/Å2 was used for the harmonic constraints. During the ﬁrst
2 ns of equilibration, a time step of 1 fs was used for the integration of
the equations of motion. After 2 ns, a time step of 1.5 fs was used, with
all the hydrogen atoms constrained using the SHAKE [41] and SETTLE
[42] algorithms. Special care was taken to equilibrate the systems in
which drug molecules were bound externally (MD3 and MD4). For
MD3 (AMN bound externally), the 4 RMN molecules were replaced
with AMN in the pdb structure 2RLF. The AMNmolecules were placed
as close as possible to the original RMN positions while trying to
maintain favorable contacts between the AMN amine group and
residue Asp44. For MD4, initial positions of RMN molecules as
reported in the NMR structure were used directly. For both MD3
and MD4 simulations, the protein and drug were held ﬁxed while the
solvent relaxed (mainly lipid) around the protein structure. This was
accomplished over a 4 ns simulation. Next, the side-chains of the
protein were released while the protein backbone and drug were held
ﬁxed for a simulation time of 2 ns. Following this, a 2 ns simulation
was carried out in which the protein backbone and drug were
constrained with weak harmonic springs (1.0 kcal/mol/Å2) while the
rest of the system was free to relax. Finally, all constraints were
removed from the system.
In all the simulations reported, periodic boundary conditions were
applied in three dimensions. The Langevin piston Nosé-Hoover
method was used to maintain a pressure of 1 atm, allowing isotropic
cell ﬂuctuations. Non-bonded interactions were calculated every time
step and full electrostatic interactions were calculated every 2 time
steps. Long-range electrostatics was taken into account via the
particle mesh Ewald (PME) scheme [43,44]. The number of grid
points in each dimension for PME was decided based on the periodic
box size, with roughly one grid point corresponding to 1 Å in each
dimension. The default value of PME direct space tolerance in NAMD
(10-6) was used.
3. Results and discussion
3.1. Internal binding site under low-pH conditions
MD simulations using the crystal structure of M2-TM in complex
with AMN (PDB code: 3C9J) performed with +3 and +4 protonation
states of the His37 tetrad (MD1 and MD2, respectively) are
representative of low-pH structures. In both of these simulations,
AMN is found to be stable at a binding site spanning the pore region
from residues Val27 to Gly34 for the entire length of the trajectories.In both low-pH systems, the hydrophobic core of AMN interacts
closely with Val27, while the AMN polar group interacts with water in
the cavity and remains mostly oriented toward the His37 gate (Figs. 1
and 3). Within this structural arrangement, it is energetically
favorable for AMN to point its polar group toward the His37 gate,
which is highly solvated. Water molecules cannot go through the
closed Val27 gate further blocked by the AMN molecule. These low-
pH simulations provide support for the orientation of AMN inside the
tetrameric bundle, which was initially inferred from the crystal
structure [17].
The simulations clearly indicate that the principal interactions
stabilizing the pore binding site of AMN at low-pH conditions are
mainly of hydrophobic nature: the adamantane core of AMN strongly
interacts with Val27 (Fig. 1). This observation also suggests that,
sharing the same hydrophobic core, RMN could likely present a
similar binding mode at the pore site. It has been commented by
Pielak et al [25] that adamantanes could not bind to the pore region in
the conformation proposed by the X-ray structure [17] due to the
presence of Ser31 residue, which would disrupt favorable hydropho-
bic interactions with AMN. Our MD simulations show that Ser31,
although pointing toward the pore lumen, cannot directly reach the
drug; it is a short side-chain and thus does not perturb the Val27/
Ala30-AMN interactions, which lock AMN in the pore (Fig. 1). The
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resistance emerged from the Ser31Asn point mutation often present
in recent inﬂuenza strains [18,19]; the longer side-chain of Asn likely
protrudes more into the pore, thus preventing adamantane binding at
the site.
3.2. External binding sites under high-pH conditions
The coordinates of one of the structures from the NMR ensemble of
RMN-bound residues 23-60 (PDB code: 2RLF) reported by Schnell and
Chou [16] were used as the initial structure for MD simulations of
externally-bound AMN (MD3) and RMN (MD4)molecules near Asp44
residues (Fig. 2). In MD3, polar groups of the four AMNmolecules drift
away from the protein at different rates during the ∼21 ns trajectory
(Fig. 2C: ∼4 ns constrained run followed by ∼17 ns of unconstrained
run). The distance between the AMN nitrogen and Asp44 Cγ atoms for
one of the AMN molecules (shown by red in Fig. 2(C)) increases
immediately after the constrained run (∼4 ns) and becomesN∼10 Å
in ∼7 ns. At this time, the drug does not interact with the protein
anymore but shows preferential interactions with the lipid head
groups and the surrounding water molecules. On the other hand, two
AMN molecules (shown by blue and green in Fig. 2(C)) stay in the
vicinity of the external binding site (AMN nitrogen-Asp44 Cγ distanceFig. 2. External binding at high pH. (A) Initial snapshot of the NMR structure [16] with f
simulation. Three AMN molecules have disassociated from the external binding sites [one of
Val27 (ice blue), Ser31 (yellow), His37 (orange), Asp44 (green) and transmembrane part (b
and Asp44 Cγ atoms of the corresponding helices with which they interacted in the initi
constrained run and entire unconstrained run; different colors are used to indicate the four
panel C.≤6 Å) for a slightly longer time but have moved far away in ∼12 ns.
However, the fourth AMN molecule (shown by black in Fig. 2(C))
seems to ﬂuctuate around the binding site (AMN nitrogen-Asp44 Cγ
distance varies between ∼4 Å and ∼10 Å) for the entire length of the
trajectory. Similar results are observed for the RMN-bound system
(MD4), in which three RMN molecules diffuse far away from
the Asp44 external binding sites during the ∼25 ns long simulation
(Fig. S1). Hence, our results indicate that the external sites do not bind
the drug molecules tightly. It should be noted that a very high
concentration of the RMN drug was used in the NMR experiment
(∼40 mM, comprising 13mol% of themicelle inwhich the proteinwas
embedded) [16]. It is possible that in the NMR micelle experiment, a
dynamic equilibrium exists in which the outgoing drug molecules are
replaced by the incoming drug molecules and the external sites
exhibit binding of the drug under conditions of high drug concentra-
tion. Indeed, Cady et al. have now shown that amantadine binds to
external sites only under high concentration and it shows 40-fold
greater afﬁnity for the internal site than the external [26]. Our MD
simulations in membranes demonstrate that drug molecules mostly
tend to drift away from external sites over tens of nanoseconds, while
they are stable at the internal site over this time scale. Hence, the
external binding sites reported for the drug molecules at the high
concentration of 40 mM likely correspond to secondary binding sitesour AMN molecules bound outside. (B) Snapshot after ∼17 ns of unconstrained MD3
these (shown by red in (C)) is out of the frame and thus cannot be seen in the image] –
lack boundaries) are shown. (C) Time evolution of the distance between AMN nitrogen
al conformation [C-term view shown in panel D]; data are shown from a part of the
AMN molecules for clarity. The black arrows in panel D point to the distances plotted in
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experiments of Jing et al. also indicate that an external binding site
is not the primary site for the pharmacological inhibition of M2 since
Asp44Ala is still sensitive to AMN, based on electrophysiological
measurements [23].
3.3. Internal binding site under high-pH conditions
During the course of the ∼17 ns-long MD3 simulation based on the
NMR structure, water molecules were seen to easily pass through the
solvated Val27 gate, in agreement with our previous MD simulations
representing high-pH conditions [27]. However, no water molecules
were detected in the cavity around Val27 in the NMR structure [16]. As
discussed by Stouffer et al. [45] perhaps the absence of NOEswithwater
molecules in this region could be due to the presence of the drug in the
cavity, with the possibility that it could not be detected in the NMR
experiments due to motional averaging. In order to test the above
hypothesis, and to explore the dynamic properties of the drug-binding
site in the central cavity under high-pH conditions, an additional MD
simulation (MD5) was performed with initial conformation chosen
from the ensemble of 15 structures reported by Schnell and Chou (PDB
code: 2RLF). The four RMN molecules were removed from the outer
surface of the protein and a single AMN was inserted in the cavity
between Val27 and Gly34 with its polar group pointing toward His37
residues. The AMN molecule rapidly tumbles during the constrained
run, and unlike under low-pH conditions, the orientation of the polar
group ﬂuctuates over a wider range during the ∼18 ns unconstrained
MD trajectory (Figs. 3 and 4). This difference in orientation can be
explained by different solvation effects found at the Val27 gate under
different pH conditions: at low pH, the His37 gate is open and solvated
whereas Val27 is tightly closed, allowing the drug to orient the amine
polar group preferentially toward the His37 residues (Fig. 1); under
high-pH conditions the Val27 gate is much more solvated and water
molecules are present in the cavity too (Fig. 4). As a result AMN tumbles
muchmore within the pore with its polar group orientation alternating
toward the two gates (Val27 and His37) under high-pH conditions.
In the drug-free state, the Val27 gate is wider in an Openout-
Closedin state allowing easy passage of water molecules [27]. In the
current MD simulation the presence of AMN impedes the transport of
water. However, intermittent formation of water wires allows some
water molecules to go through (Fig. 4). Rapid spinning of AMN about
its molecular symmetry axis is observed with a relaxation time of
∼100 ps. This behavior is also conﬁrmed by an additional simulation
of the channel model at high pH derived from the X-ray structure (D4
model) [17,27]. During the course of ∼30 ns with AMN inserted in the
cavity of the D4 model (MD6), we observe that as the pore radiusFig. 3. AMN rotation. Time evolution of theta, the angle between the C-N bond vector of AMN
runs: MD2 (black), MD5 (blue) and MD6 (green). A value of theta=180° indicates the AMaround Val27 increases, the AMN molecule tumbles to point its polar
group toward the Val27 gate (Figs. 3 and S2). A snapshot from near the
end of thisMD simulation looks similar to the one in Fig. 4A. Thus, when
the Val27 pore tends to open and M2 adopts an Openout-Closedin
conformation (∼3.5 Å, Fig. S2), both the NMR structure and the D4
structure (MD5 andMD6 simulations) show solvation of the Val27 gate
and the central cavity which in turn produces similar ﬂuctuations in
AMN polar group orientation. In agreement with our simulations, Cady
et al. have shown recently that the drug binds to the internal pore
binding site underhigh-pHconditions andundergoes signiﬁcantmotion
[26]. The results of our simulations also agree with those of Yi et al. who
reported that the C–N bond vector of AMN exhibits a wide range of
orientations inside the M2 cavity under high-pH conditions [46].
3.4. Pharmacologically relevant binding site and the development of
drug resistance
The MD simulations discussed above support the view that AMN
inhibits proton transport through M2 by binding inside the bundle
cavity as suggested by the low pH X-ray structure of Stouffer et al. [17]
and the very recent high-pH solid-state NMR structure of Cady et al.
[26]. Although the X-ray and solid-state NMR structures are for a
shorter peptide (residues 22-46) than the M2 used in the solution
NMR study (residues 23-60) [16], the present MD results yield similar
behavior for both structures. Previous studies have shown that M2-
TM (residues 22-46) forms tetrameric bundles that bind AMN,
providing strong support for using this M2-TM peptide as a minimal
model for studying proton conduction and drug binding in the M2
protein [6–9].
In the presentMD simulations, AMN stays inside theM2 cavity and
the molecular details indicate that the polar group of AMN points
toward the His37 gate under low-pH conditions. This binding site of
AMN also agrees with the previous studies that indicate the site is the
hotspot for amantadine resistant mutations [13,47]. As discussed
above, it was noted recently by Pielak et al. that the interactions of the
hydrophilic Ser31 side chain and the hydrophobic adamantane group
would be unfavorable and thus make the internal binding site difﬁcult
to reconcile [25]. They commented that it would be difﬁcult for the
hydrophobic drug to replace the water molecules present in the
absence of drug [17]. However, in the NMR structure reported by
Schnell and Chou, the Ser31 side chain does not face toward the
interior of the pore, but rather interacts with the neighboring helices
[16,25]. In the AMN-bound X-ray crystal structure, and in MD
simulations based on it, Ser31 does point toward the interior but
enough space remains in the cavity that is occupied by water
molecules in the absence of AMN. Moreover, the phenomena of aand the bilayer normal (z-axis) are shown for three simulations for the unconstrained
N polar group is oriented toward the C-terminus (His37 gate).
Fig. 4. Internal binding at high pH. Snapshot of the simulation with AMN in the channel cavity of NMR structure (MD5) with Val27 (ice blue), Ser31 (yellow), His37 (orange) and the
transmembrane region (black boundaries) indicated. (A) Front view, (B) N-term view. (C, D, E) Three representative snapshots showing the intermittent formation of water wires
and ﬂuctuation in the AMN polar group orientation.
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present inside a channel cavity have been observed previously in the
case of KcsA K+ channel [48]. In the X-ray structure, the hydrophobic
interactions of the adamantane group with the other amino acids
present at the internal drug binding site, especially Val27, likely lead
to the stabilization of the drug at this site. Our MD simulations show
that the drug is stable at the internal site in both the X-ray structures
(MD1 and MD2) and the NMR structure (MD5).
On the other hand, in MD simulations of the membrane-bound
bundle of M2 with residues 23–60, drug molecules do not exhibit
strong binding at the external sites observed in the NMR micelle
study [16]. However, as discussed above, the high concentration of
the drug in the NMR experiments (13% of the micellar components)
and the strong partitioning of the drug in the micelle [45] likely
explain the observation of NOEs due to drug molecules. Moreover,
the notion that the external binding sites are the pharmacologically
relevant ones is inconsistent with many previous studies. For
example, the drug inhibits proton transport by binding to the
channel with a stoichiometry of one drug to one tetramer [32,33]
and not four drugs to one tetramer. A strong evidence in support for
the internal binding site being pharmacologically relevant comes
from the very recent solid-state NMR experiments that demonstrate
that AMN is bound at the internal site at a stoichiometry of one drug
to one tetramer and stays bound when the drug concentration is
increased [26]. Our results from present MD simulations provide
evidence that AMN and RMN interactions with Asp44 are not very
stable in the membrane environment and tend to mostly disrupt on
the multi-ns timescale.Stouffer et al. suggested that the absence of NOEs in ∼7 Å wide
pore in the NMR structure could be due to the motional averaging of
the drug molecule at this site [45]. The present MD simulations show
that the drug molecule at this site indeed exhibits dynamic rotation in
various orientations under the relevant high-pH conditions. It was
proposed by Schnell and Chou that the drug resistant mutation
Ser31Asn stabilizes the open conformation. Contrary to this hypoth-
esis, Stouffer et al. have shown that the speciﬁc activity of Ser31Asn is
very similar to the wild-type [45]. Also, the electrophysiological
experiments by Jing et al. show that the mutations of speciﬁc residues
that interact with the drug in the NMR structure, Asp44Ala and
Arg45Ala, exhibit AMN sensitivity [23]. More recently, it has also been
shown that mutations of residues that are N-terminal to His37 exhibit
signiﬁcantly lower inhibition by AMN while most mutations of Trp41
and Asp44 had little or no effect on AMN inhibition, indicating that the
external binding sites are not the primary sites associated with the
pharmacological inhibition of M2 [24]. Thus, preponderance of the
experimental evidence along with the present MD simulations
supports the view that the pharmacologically relevant binding site
is located inside the cavity as opposed to the protein bundle external
surface.
4. Conclusions
The present MD simulations are consistent with our recent
proposal that the M2 protein shows pH-dependent transporter-like
properties modulated by the opening and closing of Val27 and His37
gates [27]. In particular, the simulations suggest that two different
Fig. 5. Schematic representation of AMN blocking modes at low- and high-pH. Val27
(purple) and His37 (orange) gates are shown. Under high-pH conditions Openout-
Closedin state is dominant, AMN largely prevents proton transport to His37 gate in this
state by blocking the Val27 gate and the orientation of AMN polar group (dark blue)
ﬂuctuates between the two gates. If, however, protons reach the His37 gate, the
Closedout-Openin conformation is favored in which AMN is mostly oriented toward the
His37 gate. After the release of protons to the viral interior, the Openout-Closedin state is
favored again.
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distinct states of conduction suggested in a transporter-like mecha-
nism (Fig. 5). Under high-pH conditions, when the Val27 gate is open
and solvated (Openout-Closedin state), AMN can likely ﬁnd a favorable
entrance and accommodates in the cavity, where the orientation of its
polar group ﬂuctuates. In this conformation AMN could severely limit
proton conduction into the viral interior by preventing the proton-
ation of His37 residues due to steric hindrance at the Val27 gate,
essentially locking M2 in the Openout-Closedin state. Cross and co-
workers showed that AMN binding lowers the pKa of the His37
residues by about three orders of magnitude compared to the ﬁrst pKa
of His37 in drug free M2-TM [6]. The change in pKa on AMN binding
could also contribute to inhibition of proton transport.
In the event that some protons are able to penetrate inside the M2
cavity via intermittent water wires and the His37 gate becomes
charged and opens, the Val27 gate would close (Closedout-Openin
state). In this conformation the hydrophobic group of AMN exhibits
strong interactions with the closed Val27 gate. Its polar group points
toward His37 and is solvated by water molecules in the bundle
interior. AMN completely blocks the water (and proton) transport
through the Val27 gate under these conditions. AMN could lock the
conformation in this Closedout-Openin state or if the equilibrium shifts
back to the Openout-Closedin state after release of protons to the viral
interior, AMN would still inhibit proton transport due to steric effects
and alteration of His37 pKa as discussed above.
Based on the dynamic features obtained from the MD simulations,
AMN uptake would likely be more difﬁcult in the Closedout-Openin
state, thus AMNmay preferentially bind to M2 when the channel is in
the Openout-Closedin state at high-pH conditions, which is consistent
with the higher drug afﬁnity at higher pH [7,10]. Because of the
structural similarity between AMN and RMN, RMN will likely exhibit
the same behavior in the channel pore, hence blocking the proton
transport by a similar mechanism.
In conclusion, our MD simulations agree with the prevailing view
that adamantane drugs block proton transport throughM2 by binding
inside the cavity [17,23,26]. AMN uptake at the pore binding site likely
occurs when the Val27 gate is open and the His37 gate is closed (i.e.,
mostly in high-pH state). We propose different modes of binding
depending on the protonation state of His37 gate, which are
consistent with the recently proposed kinetic model for protonconduction through a transporter-like mechanism [27]. The proton
transport to the viral interior is inhibited in both the modes via
blocking of proton passage through the Val27 gate. The highly
persistent Ser31Asn mutation at this site in adamantane-resistant
strains of inﬂuenza A virus, as present in recent avian and swine ﬂu
strains also [18,19], would then explain the reduction in adamantane
drug binding afﬁnity as has been discussed previously [17,21,23,49].
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